Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + rosuvastatin (Hanmi Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
metformin + rosuvastatin is a fixed-dose combination (FDC) therapy developed by Hanmi Pharmaceutical for the management of comorbid type 2 diabetes mellitus and hypercholesterolemia (dyslipidemia). Metformin is a biguanide antihyperglycemic agent that lowers blood glucose levels primarily by decreasing hepatic glucose production and increasing peripheral insulin sensitivity through the activation of AMP-activated protein kinase (AMPK). Rosuvastatin is a potent HMG-CoA reductase inhibitor (statin) that reduces cholesterol biosynthesis in the liver, leading to decreased levels of low-density lipoprotein (LDL) cholesterol and triglycerides. This combination is designed to improve patient compliance and therapeutic outcomes in individuals requiring simultaneous control of glucose and lipid levels, which are frequently co-occurring conditions in metabolic syndrome.
- Brand names
- Rosumet
- Other names
- metformin hydrochloride + rosuvastatin calcium
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on metformin + rosuvastatin (Hanmi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + rosuvastatin (Hanmi Pharmaceutical).